natgillin/translations-raw huggingface dataset:
A dental examination and appropriate preventive dentistry should be considered prior to starting the treatment with MVASI. 
Pred začetkom zdravljenja z zdravilom MVASI je treba razmisliti o pregledu zobovja in primernih preventivnih zobozdravstvenih posegih.
Renal thrombotic microangiopathy, which may be clinically manifested as proteinuria (not known) with or without concomitant sunitinib use. 
Žilne bolezni renalna trombotična mikroangiopatija, ki se lahko klinično izrazi kot proteinurija (ni znana) pri sočasni uporabi sunitiniba ali brez; za dodatne informacije glede proteinurije glejte poglavje 4.4 in odstavek Proteinurija v poglavju 4.8
Efficacy results for trial BO17704 Cisplatin/Gemcitabine + placebo 
BO17705 placebo + interferona bevacizumabb + interferona
• blocking of the blood vessels of the lungs by a blood clot, 
• zamašitev krvnih žil v pljučih s krvnim strdkom,
This study was designed as an open-label, randomised, two-arm phase III evaluation of bevacizumab plus chemotherapy (CT + BV) versus chemotherapy alone (CT). 
Študija je bila zasnovana kot odprto, randomizirano preskušanje faze III z dvema skupinama, v katerem so ocenjevali zdravljenje z bevacizumabom in kemoterapijo v primerjavi s samo kemoterapijo.
In NSABP C-08, a phase III trial of bevacizumab in adjuvant treatment of patients with colon cancer, the incidence of new cases of ovarian failure, defined as amenorrhoea lasting 3 or more months, FSH level ≥ 30 mIU/mL and a negative serum β-HCG pregnancy test, has been evaluated in 295 premenopausal women. 
V kliničnem preskušanju faze III (NSABP C-08) bevacizumaba v adjuvantnem zdravljenju pri bolnikih z rakom na debelem črevesu so incidenco novih primerov okvare jajčnikov ocenjevali pri 295 predmenopavzalnih ženskah.
In a trial of patients with persistent, recurrent or metastatic cervical cancer, the incidence of GI-vaginal fistulae was 8.3% in bevacizumab-treated patients and 0.9% in control patients, all of whom had a history of prior pelvic radiation. 
V preskušanju pri bolnicah z rakom materničnega vratu, pri katerih je bila bolezen prisotna tudi po zaključenem primarnem zdravljenju, se je ponovila ali je bila metastatska, je bila incidenca fistul med prebavili in nožnico 8,3 % med prejemnicami bevacizumaba in 0,9 % pri bolnicah v kontrolni skupini; vse te bolnice so imele v anamnezi obsevanje medeničnega predela.
Pulmonary haemorrhage/ Haemoptysisa,b, Pulmonary embolism, Epistaxis, Dyspnoea, Hypoxia 
Bolezni dihal, prsnega koša in mediastinalnega prostora krvavitev v pljučih/hemoptizaa,b, pljučna embolija, epistaksa, dispneja, hipoksija pljučna hipertenzijac, perforacija nosnega pretinac
MVASI in combination with paclitaxel, topotecan, or pegylated liposomal doxorubicin is indicated for the treatment of adult patients with platinum-resistant recurrent epithelial ovarian, fallopian tube, or primary peritoneal cancer who received no more than two prior chemotherapy regimens and who have not received prior therapy with bevacizumab or other VEGF inhibitors or VEGF receptor-targeted agents (see section 5.1). 
Zdravilo MVASI je v kombinaciji s paklitakselom, topotekanom ali pegiliranim liposomalnim doksorubicinom indicirano za zdravljenje odraslih bolnic s ponovitvijo epitelijskega raka jajčnikov, karcinoma jajcevodov ali primarnega peritonealnega karcinoma, rezistentnega na platino, ki so predhodno prejele največ dve shemi kemoterapije, z bevacizumabom ali drugimi zaviralci VEGF ali zdravili, ki delujejo na receptor VEGF, pa se še niso zdravile (glejte poglavje 5.1).
The median overall survival was 20.3 months in placebo and 21.2 months in bevacizumab-treated patients in the FOLFOX treatment subgroup, HR = 0.94, 97.5% CI = [0.75; 1.16]; p-value = 0.4937, the corresponding results in the XELOX, treatment subgroup being 19.2 vs. 21.4 months, HR = 0.84, 97.5% CI = [0.68; 1.04]; p-value = 0.0698. 
Mediana celokupnega preživetja je pri bolnikih v podskupini, ki se je zdravila po shemi FOLFOX, znašala 20,3 meseca, če so prejemali placebo, in 21,2 meseca, če so se zdravili z bevacizumabom: razmerje ogroženosti = 0,94; 97,5-% interval zaupanja = [0,75; 1,16]; p-vrednost = 0,4937.
• AVF4095g evaluated the efficacy and safety of bevacizumab in combination with carboplatin and gemcitabine followed by bevacizumab as a single agent in patients with platinum-sensitive recurrent epithelial ovarian, fallopian tube or primary peritoneal cancer. 
• Preskušanje AVF4095g je ocenjevalo učinkovitost in varnost bevacizumaba v kombinaciji s karboplatinom in gemcitabinom, ki jim je sledil bevacizumab samostojno, pri bolnicah s ponovitvijo epitelijskega raka jajčnikov, karcinoma jajcevodov ali primarnega peritonealnega karcinoma, občutljivega na platino.
The majority of patients had serous adenocarcinoma histologic type (85% in CPP and CPB15, 86% in CPB15+). 
(85 % v CPP in CPB15, 86 % v CPB15+ skupini).
Very common Common 
Zelo redki
The recommended dose of MVASI when used in addition to erlotinib is 15 mg/kg of body weight given once every 3 weeks as an intravenous infusion. 
Priporočeni odmerek zdravila MVASI, ko ga uporabljamo kot dodatek erlotinibu, je 15 mg/kg telesne mase v enkratnem odmerku na 3 tedne, v obliki intravenske infuzije.
Metastatic carcinoma of the colon or rectum (mCRC) The recommended dose of MVASI, administered as an intravenous infusion, is either 5 mg/kg or 10 mg/kg of body weight given once every 2 weeks or 7.5 mg/kg or 15 mg/kg of body weight given once every 3 weeks. 
Priporočeni odmerek zdravila MVASI, apliciranega v obliki intravenske infuzije, je 5 mg/kg ali 10 mg/kg telesne mase v enkratnem odmerku vsaka 2 tedna ali 7,5 mg/kg ali 15 mg/kg telesne mase v enkratnem odmerku vsake 3 tedne.
Thromboembolism (see section 4.4) 
Trombembolija (glejte poglavje 4.4)
• blocking of the veins of the legs by a blood clot, 
• zamašitev ven v nogah s krvnim strdkom,
In patients with NSCLC excluding predominant squamous histology, all grade reactions were seen with a frequency of up to 9.3% when treated with bevacizumab plus chemotherapy compared with up to 5% in the patients treated with chemotherapy alone. 
Pri bolnikih z nedrobnoceličnim rakom pljuč so, razen pri predominantni skvamozni histologiji, neželene učinke vseh stopenj opazili s pogostnostjo do 9,3 %, če so jih zdravili z bevacizumabom in kemoterapijo.
400 mg/m2 IV bolus, 600 mg/m2 IV 22 h 
v bolusu, sledi 600 mg/m2 i.v.
Congestive heart failure (CHF) (see section 4.8) 
Kongestivno srčno popuščanje (glejte poglavje 4.8)
The recommended dose of MVASI is 10 mg/kg of body weight given once every 2 weeks or 15 mg/kg of body weight given once every 3 weeks as an intravenous infusion. 
Priporočeni odmerek zdravila MVASI je 10 mg/kg telesne mase v enkratnem odmerku vsaka 2 tedna ali 15 mg/kg telesne mase v enkratnem odmerku vsake 3 tedne, v obliki intravenske infuzije.
Topotecan + Paclitaxel vs. Cisplatin + Paclitaxel 
Topotekan + paklitaksel proti cisplatin + paklitaksel
• MO22224 evaluated the efficacy and safety of bevacizumab in combination with paclitaxel, topotecan, or pegylated liposomal doxorubicin in patients with platinum-resistant recurrent epithelial ovarian, fallopian tube or primary peritoneal cancer. 
• Preskušanje MO22224 je ocenjevalo učinkovitost in varnost bevacizumaba v kombinaciji s paklitakselom, topotekanom ali pegiliranim liposomalnim doksorubicinom pri bolnicah s ponovitvijo epitelijskega raka jajčnikov, karcinoma jajcevodov ali primarnega peritonealnega karcinoma, rezistentnega na platino.
An increased incidence of CHF has been observed in a clinical trial of patients with diffuse large B-cell lymphoma when receiving bevacizumab with a cumulative doxorubicin dose greater than 300 mg/m2. 
V kliničnem preskušanju, ki je vključevalo bolnike z difuznim velikoceličnim B limfomom, ki so prejemali bevacizumab skupaj s kumulativnim odmerkom doksorubicina, ki je presegal 300 mg/m2, so opazili večjo incidenco kongestivnega srčnega popuščanja.
This was a phase II randomised, active-controlled, open-labelled clinical trial investigating bevacizumab in combination with 5-FU/FA as first-line treatment of metastatic colorectal cancer. 
To je bilo randomizirano, aktivno kontrolirano, odprto klinično preskušanje faze II, v katerem so proučevali kombinacijo bevacizumaba s 5-FU/FA kot prvo linijo zdravljenja metastatskega raka debelega črevesa in danke.
MVASI is also used for the treatment of adult patients with advanced non-small cell lung cancer. 
Zdravilo MVASI uporabljamo tudi za zdravljenje odraslih bolnikov z napredovalim nedrobnoceličnim rakom pljuč.
In a randomised phase II study (BO25041) a total of 121 patients aged ≥ 3 years to < 18 years with newly diagnosed supratentorial or infratentorial cerebellar or peduncular high-grade glioma (HGG) were treated with post-operative radiation therapy (RT) and adjuvant temozolomide (T) with and without bevacizumab: 10 mg/kg every 2 weeks IV. 
V randomizirani študiji faze II (BO25041) so s pooperativno radioterapijo in adjuvantnim temozolomidom v kombinaciji z intravenskim bevacizumabom (v odmerku 10 mg/kg vsaka dva tedna) ali brez njega zdravili skupno 121 bolnikov, starih od ≥ 3 do < 18 let, z novo diagnosticiranim supratentorialnim ali infratentorialnim cerebralnim ali pedunkularnim gliomom visoke stopnje.
The addition of bevacizumab 5 mg/kg every two weeks to 5-FU/FA resulted in higher objective response rates, significantly longer progression-free survival, and a trend in longer survival as compared to 5-FU/FA chemotherapy alone. 
Dodatek 5 mg bevacizumaba/kg telesne mase vsake dva tedna h kemoterapiji po shemi 5-FU/FA je povečal objektivni odgovor na zdravljenje in značilno podaljšal preživetje brez napredovanja bolezni.
95% CI 
95-% interval zaupanja
Secondary endpoints Progression-free survival - Primary analysis6 Median PFS (months)1 Hazard ratio [95% CI] 
(vrednost p5,8 = 0,0126) Sekundarni opazovani dogodki Preživetje brez napredovanja bolezni - primarna analiza6 Mediana preživetja brez napredovanja (meseci)1 Razmerje ogroženosti [95-% IZ]
(14.9 vs. 17.5 months; p = 0.4146) 
(14,9 proti 17,5 meseca; p =
Cisplatin + Paclitaxel 
Cisplatin + paklitaksel
Clear to slightly opalescent, colourless to slightly yellow liquid. 
FARMACEVTSKA OBLIKA koncentrat za raztopino za infundiranje Bistra do rahlo motna, brezbarvna do rahlo rumena tekočina.
Gall bladder perforation (not known) 
Bolezni prebavil razjeda v prebavilih (ni znana)
• The protocol-specified analysis of investigator assessed PFS (without censoring for CA-125 progression or non-protocol therapy [NPT]) shows a stratified hazard ratio of 0.71 (95% CI: 0.61-0.83, 1-sided log-rank p-value < 0.0001) when CPB15+ is compared with CPP, with a median PFS of 10.4 months in the CPP arm and 14.1 months in the CPB15+ arm. 
• S protokolom opredeljena analiza preživetja brez napredovanja bolezni, ocenjena s strani raziskovalca (brez krnjenih podatkov za napredovanje bolezni glede na CA 125 ali zdravljenja, ki ni bilo v skladu s protokolom) kaže stratificirano razmerje ogroženosti 0,71 (95-% interval zaupanja: 0,61-0,83; p-vrednost za enostranski log rank test < 0,0001) ko primerjamo CPB15+ s CPP, z mediano preživetja brez napredovanja bolezni 10,4 meseca v CPP skupini in 14,1 meseca v CPB15+ skupini.
In patients developing PRES, treatment of specific symptoms including control of hypertension is recommended along with discontinuation of MVASI. 
Če se pri bolniku pojavi sindrom posteriorne reverzibilne encefalopatije, je poleg prekinitve zdravljenja z zdravilom MVASI priporočljivo zdravljenje specifičnih simptomov, vključno z uravnavo hipertenzije.
The number of infusions that you receive will depend on how you are responding to treatment; you should continue to receive this medicine until MVASI fails to stop your tumour growing. 
Število infuzij, ki jih boste prejeli, je odvisno od vašega odziva na zdravljenje.
• MVASI can increase the risk of developing a weak heart. 
• zdravilo MVASI lahko poveča tveganje za opešanje srca.
This was a phase III randomised, controlled, open-label trial investigating bevacizumab 5.0 mg/kg every 2 weeks or 7.5 mg/kg every 3 weeks in combination with fluoropyrimidine-based chemotherapy versus fluoropyrimidine-based chemotherapy alone in patients with mCRC who have progressed on a first-line bevacizumab-containing regimen. 
To je bilo randomizirano, kontrolirano, odprto preskušanje faze III, s katerim so pri bolnikih z metastatskim rakom debelega črevesa in danke, pri katerih je po prvi liniji zdravljenja z bevacizumabom prišlo do napredovanja bolezni, proučevali bevacizumab v odmerku 5,0 mg/kg telesne mase vsaka 2 tedna ali v odmerku 7,5 mg/kg telesne mase vsake 3 tedne v kombinaciji s kemoterapijo, osnovano na fluoropirimidinu, v primerjavi s samostojno kemoterapijo na osnovi fluoropirimidina.
The recommended dose of MVASI is 7.5 mg/kg or 15 mg/kg of body weight given once every 3 weeks as an intravenous infusion. 
Priporočeni odmerek zdravila MVASI je 7,5 mg/kg telesne mase ali 15 mg/kg telesne mase v enkratnem odmerku na 3 tedne, v obliki intravenske infuzije.
Paclitaxel (n = 354) 
paklitaksel (n = 354)
• The analysis of PFS as determined by the independent review committee (censoring for NPT) shows a stratified hazard ratio of 0.62 (95% CI: 0.50-0.77, 1-sided log-rank p-value < 0.0001) when CPB15+ is compared with CPP, with a median PFS of 13.1 in the CPP arm and 19.1 months in the CPB15+ arm. 
• Analiza preživetja brez napredovanja bolezni, kot jo je določil odbor za neodvisni pregled (s krnjenimi podatki za zdravljenje, ki ni bilo v skladu s protokolom) kaže stratificirano razmerje ogroženosti 0,62 (95-% interval zaupanja: 0,50-0,77; p-vrednost za enostranski log rank test < 0,0001) ko primerjamo CPB15+ s CPP, z mediano preživetja brez napredovanja bolezni 13,1 v CPP skupini in 19,1 meseca v CPB15+ skupini.
You may be advised to have a dental check-up before you start treatment with MVASI. 
Pred začetkom zdravljenja z zdravilom MVASI boste morda morali opraviti pregled zob.
Overall survival - Primary analysis1 Hazard ratio (95% CI) 
Drugi faktor Celokupno preživetjeprimarna analiza1 Razmerje ogroženosti (95-% IZ)
Grade 3-5 reactions have been observed in up to 2.3% of patients treated with bevacizumab plus chemotherapy as compared with < 1% with chemotherapy alone (NCI-CTCAE v.3). 
Neželene učinke stopnje 3 do 5 so opazili pri do 2,3 % bolnikov, ki so bili zdravljeni z bevacizumabom in kemoterapijo (NCI-CTCAE v.3).
In the FOLFOX treatment subgroup, the median PFS was 8.6 months in placebo and 9.4 months in bevacizumab-treated patients, HR = 0.89, 97.5% CI = [0.73; 1.08]; p-value = 0.1871, the corresponding results in the XELOX treatment subgroup being 7.4 vs. 9.3 months, HR = 0.77, 97.5% CI = [0.63; 0.94]; p-value = 0.0026. 
V podskupini, ki je prejemala zdravljenje po shemi FOLFOX, je bila mediana preživetja brez napredovanja bolezni 8,6 meseca pri bolnikih, ki so prejemali placebo, ter 9,4 meseca pri bolnikih, ki so se zdravili z bevacizumabom; razmerje ogroženosti = 0,89, 97,5-% interval zaupanja = [0,73; 1,08]; p-vrednost = 0,1871.
Progression-free survival1 
Preživetje brez napredovanja bolezni1
This was a randomised, double-blind, phase II clinical trial investigating bevacizumab 10 mg/kg in a 2 weekly schedule with the same dose of bevacizumab in combination with 150 mg daily erlotinib, in patients with metastatic clear cell RCC. A total of 104 patients were randomised to treatment in this trial, 53 to bevacizumab 10 mg/kg every 2 weeks plus placebo and 51 to bevacizumab 10 mg/kg every 2 weeks plus erlotinib 150 mg daily. 
Skupno so v zdravljenje v tem preskušanju randomizirali 104 bolnike; 53 v skupino, ki je prejemala bevacizumab 10 mg/kg vsake 2 tedna in placebo, ter 51 v skupino, ki je prejemala bevacizumab 10 mg/kg vsake 2 tedna in 150 mg erlotiniba na dan.
(17.5 vs.15.0 months; p = 0.0584) 
(17,5 proti 15,0 meseca; p =
,b 
,d,
• CP arm: Carboplatin (AUC 6) and paclitaxel (175 mg/m2) for 6 cycles of 3 weeks duration. 
• CP skupina: 6 tritedenskih ciklov karboplatina (AUC 6) in paklitaksela (175 mg/m2).
Severe reactions are defined as adverse events with at least a 2% difference compared to the control arm in clinical studies for NCI-CTCAE grade 3-5 reactions. 
Hudi neželeni učinki so tisti neželeni učinki stopnje 3 do 5 po lestvici NCI-CTCAE, ki so se pojavili z najmanj 2-% razliko v primerjavi s kontrolno skupino v kliničnih preskušanjih.
• CPB15 arm: Five cycles of bevacizumab (15 mg/kg q3w started cycle 2) in combination with carboplatin (AUC 6) and paclitaxel (175 mg/m2) for 6 cycles followed by placebo alone, for a total of up to 15 months of therapy 
• CPB15 skupina: pet ciklov bevacizumaba (15 mg/kg telesne mase enkrat na 3 tedne, z začetkom v ciklu 2) v kombinaciji s karboplatinom (AUC 6) in 6 cikli paklitaksela (175 mg/m2), katerim je sledil samo placebo do skupno 15 mesecev zdravljenja.
In addition, a pre-specified analysis of the data censoring for CA-125 progression events was conducted, as well as an independent review of PFS as determined by radiological scans. 
Poleg tega je bila opravljena vnaprej določena analiza v kateri niso uporabili podatkov za dogodke napredovanja bolezni glede na CA 125.
Relative to the control arm. 
b glede na kontrolno skupino.
• CP arm: Carboplatin (AUC5) and paclitaxel (175 mg/m2 IV) every 3 weeks for 6 and up to 
• skupina CP: karboplatin (AUC5) in paklitaksel (175 mg/m2 intravensko) vsake 3 tedne, od 6 do največ 8 ciklov.
• Paclitaxel 175 mg/m2 IV over 3 hours on day 1 and topotecan 0.75 mg/m2 IV over 30 minutes on days 1-3 plus bevacizumab 15 mg/kg IV on day 1 (q3w) 
• paklitaksel 175 mg/m2 intravensko v 3-urni infuziji 1. dan in topotekan 0,75 mg/m2 intravensko v 30 minutah od 1. do 3. dne (na 3 tedne) ter bevacizumab 15 mg/kg intravensko 1. dan (na 3 tedne).
Paclitaxel/ bevacizumab (n = 252) 
paklitaksel/ bevacizumab (n = 252)
As bevacizumab may adversely impact wound healing, patients who had major surgery within the last 28 days were excluded from participation in phase III clinical trials. 
Bolniki, ki so imeli večjo operacijo v zadnjih 28 dneh pred pričetkom zdravljenja, niso bili vključeni v klinična preskušanja faze III, saj lahko bevacizumab negativno vpliva na celjenje ran.
• a blood clot in the blood vessels of your lungs, 
• krvni strdek v krvnih žilah pljuč,
CT (n = 144) 
kemoterapija (n = 144)
Prior radiation is a major risk factor for the development of GI-vaginal fistulae and all patients with GI-vaginal fistulae had a history of prior radiation. 
Predhodno obsevanje je velik dejavnik tveganja za nastanek fistule med prebavili in nožnico; vse bolnice s fistulo med prebavili in nožnico so bile predhodno obsevane.
Venous thromboembolism (see section 4.8) 
Venska trombembolija (glejte poglavje 4.8)
The recommended dose of MVASI is 10 mg/kg of body weight given once every 2 weeks as an intravenous infusion. 
Priporočeni odmerek zdravila MVASI je 10 mg/kg telesne mase v enkratnem odmerku vsaka 2 tedna, v obliki intravenske infuzije.
From a clinical trial in patients with persistent, recurrent, or metastatic cervical cancer (GOG-0240), 1.8% of bevacizumab-treated patients and 1.4% of control patients were reported to have had nongastrointestinal vaginal, vesical, or female genital tract fistulae. 
V kliničnem preskušanju pri bolnicah z rakom materničnega vratu, pri katerih je bila bolezen prisotna tudi po zaključenem primarnem zdravljenju, se je ponovila ali je bila metastatska (študija GOG-240), je imelo fistule med nožnico, mehurjem ali ženskimi spolovili in organi izven prebavil 1,8 % prejemnic bevacizumaba in 1,4 % bolnic v kontrolni skupini.
Paclitaxel/ bevacizumab (n = 229) 
paklitaksel/ bevacizumab (n = 229)
130 mg/m2 IV 2 h 
Oksaliplatin 130 mg/m2 i.v.
Paclitaxel 175 mg/m2 IV over 3 hours on day 1 and cisplatin 50 mg/m2 IV on day 2 (q3w); or Paclitaxel 175 mg/m2 IV over 3 hours on day 1 and cisplatin 50 mg/m2 IV on day 1 (q3w) 
• paklitaksel 135 mg/m2 intravensko v 24-urni infuziji 1. dan in cisplatin 50 mg/m2 intravensko 2. dan na 3 tedne, ali paklitaksel 175 mg/m2 intravensko v 3-urni infuziji 1. dan in cisplatin 50 mg/m2 intravensko 2. dan (na 3 tedne), ali paklitaksel 175 mg/m2 intravensko v 3-urni infuziji 1. dan in cisplatin 50 mg/m2 intravensko 1. dan (na 3 tedne);
First-line treatment of non-squamous NSCLC in combination with platinum-based chemotherapy MVASI is administered in addition to platinum-based chemotherapy for up to 6 cycles of treatment followed by MVASI as a single agent until disease progression. 
Zdravilo MVASI dodajamo h kemoterapiji, osnovani na platini, do 6 ciklov, nato pa zdravilo MVASI dajemo samostojno do napredovanja bolezni.
Patients treated for persistent, recurrent, or metastatic cervical cancer with bevacizumab are at increased risk of fistulae between the vagina and any part of the GI tract (Gastrointestinal-vaginal fistulae). 
Bolnice z rakom materničnega vratu, pri katerih je bolezen prisotna tudi po zaključenem primarnem zdravljenju, se je ponovila ali je metastatska, in se zdravijo z bevacizumabom, imajo večje tveganje za nastanek fistule med nožnico in katerim koli delom prebavil (fistule med prebavili in nožnico).
MVASI is also used for treatment of adult patients with advanced kidney cancer. 
Zdravilo MVASI uporabljamo tudi za zdravljenje odraslih bolnikov z napredovalim rakom ledvičnih celic.
Progression-free survival Median (months) Hazard ratio (95% confidence interval) 
Preživetje brez napredovanja bolezni mediana (meseci) razmerje ogroženosti 95-% interval zaupanja
• CPB15+ arm: Five cycles of bevacizumab (15 mg/kg q3w started cycle 2) in combination with carboplatin (AUC 6) and paclitaxel (175 mg/m2) for 6 cycles followed by continued use of bevacizumab (15 mg/kg q3w) as single agent for a total of up to 15 months of therapy. 
• CPB15+ skupina: pet ciklov bevacizumaba (15 mg/kg telesne mase enkrat na 3 tedne, z začetkom v ciklu 2) v kombinaciji s karboplatinom (AUC 6) in 6 cikli paklitaksela (175 mg/m2), katerim je sledilo zdravljenje samo z bevacizumabom (15 mg/kg telesne mase enkrat na 3 tedne) do skupno 15 mesecev zdravljenja.
In one clinical trial evaluating bevacizumab in combination with 5-fluorouracil/folinic acid, AVF2192g, patients with metastatic colorectal cancer who were not candidates for treatment with irinotecan were included. 
Bolniki z metastatskim rakom debelega črevesa in danke, ki niso bili primerni za zdravljenje z irinotekanom, so bili vključeni v klinično preskušanje AVF2192g, ki je ocenjevalo bevacizumab v kombinaciji s 5-fluorouracilom oziroma folinsko kislino.
EGFR monoclonal antibodies in combination with bevacizumab chemotherapy regimens 
Monoklonska protitelesa z delovanjem na EGFR, v kombinaciji s kemoterapevtskimi shemami, ki vključujejo bevacizumab
In study BO25041 of bevacizumab added to post-operative radiation therapy (RT) with concomitant and adjuvant temozolomide in paediatric patients with newly diagnosed supratentorial, infratentorial, cerebellar, or peduncular high-grade glioma, the safety profile was comparable with that observed in other tumour types in adults treated with bevacizumab. 
V študiji BO25041 z bevacizumabom, dodanim pooperativni radioterapiji s sočasno in adjuvantno uporabo temozolomida pri pediatričnih bolnikih z novo diagnosticiranim supratentorialnim,
Median (months) Hazard ratio [95% CI] 
Mediana (meseci)1 Razmerje ogroženosti [95-% IZ]
Patients were randomised to paclitaxel alone (90 mg/m2 / IV over 1-hour once weekly for three out of four weeks) or in combination with bevacizumab (10 mg/kg IV infusion every two weeks). 
v 1 uri enkrat tedensko tri od štirih tednov) ali v skupino, ki je prejemala kombinacijo paklitaksela in bevacizumaba (10 mg/kg z intravensko infuzijo vsaka dva tedna).
Median PFS (months) Hazard ratio (95% CI)4 Randomised patients with stage IV disease CPP (n = 153) 
Randomizirane bolnice z boleznijo stadija IV CPP (n = 153)
Cervical cancer 
Rak materničnega vratu
Median PFS (months) Hazard ratio (95% CI)4 Randomised patients with stage III suboptimally debulked disease3 CP (n = 154) 
Randomizirane bolnice s suboptimalno citoredukcijo, stadija III3 CP (n = 154)